Irbesartan ameliorates diabetic nephropathy by reducing the expression of connective tissue growth factor and alpha-smooth-muscle actin in the tubulointerstitium of diabetic rats

Pharmacology

Volumn 83, Issue 2, 2009, Pages 80-87

  Ren, Xiaojun ^a   Guan, Guangju ^a   Liu, Gang ^a   Liu, Gaohong ^b  

^a SHANDONG UNIVERSITY   (China)

^b SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

Author keywords

Smooth muscle actin; Connective tissue growth factor; Diabetic nephropathy; Irbesartan; Myofibroblasts

Indexed keywords

ALBUMIN; ALPHA SMOOTH MUSCLE ACTIN; CONNECTIVE TISSUE GROWTH FACTOR; GLUCOSE; IRBESARTAN; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DRUG MECHANISM; DRUG TARGETING; FIBROSIS; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INTERSTITIUM; KIDNEY MASS; KIDNEY PARENCHYMA; KIDNEY TUBULE; MALE; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; URINE LEVEL; WESTERN BLOTTING; WISTAR RAT;

ACTINS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BIPHENYL COMPOUNDS; BLOOD GLUCOSE; CONNECTIVE TISSUE GROWTH FACTOR; CREATININE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; KIDNEY; MALE; NEPHRITIS, INTERSTITIAL; RATS; RATS, WISTAR; SERUM ALBUMIN; TETRAZOLES;

EID: 57149136704     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000180123     Document Type: Article

References (35)

1. Schrijvers BF, De Vriese AS, Flyvbjerg A: From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 2004;25:971-1010.
2. Schena FP, Gesualdo L: Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol 2005;16:S30-S33.
3. Mason RM, Wahab NA: Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 2003;14:1358-1373.
4. Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331:1286-1292.
5. 1 oligodoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice. Am J Physiol Renal Physiol 2000;278:F628-F634.
6. Sharma K, Jin Y, Guo J, Ziyadeh FN: Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996;45:522-530.
7. Gupta S, Clarkson MR, Duggan J, Brady HR: Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int 2000;58:1389-1399.
8. Kobayashi T, Inoue T, Okada H, Kikuta T, Kanno Y, Nishida T, Takigawa M, Sugaya T, Suzuki H: Connective tissue growth factor mediates the profibrotic effects of transforming growth factor-beta produced by tubular epithelial cells in response to high glucose. Clin Exp Nephrol 2005;9:114-121.
9. Wahab NA, Yevdokimova N, Weston BS, Roberts T, Li XJ, Brinkman H, Mason RM: Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy. Biochem J 2001;359:77-87.
10. Yokoi H, Mukoyama M, Nagae T, Mori K, Suganami T, Sawai K, Yoshioka T, Koshikawa M, Nishida T, Takigawa M, Sugawara A, Nakao K: Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J Am Soc Nephrol 2004;15:1430-1440.
11. Thomas MC, Burns WC, Cooper ME: Tubular changes in early diabetic nephropathy. Adv Chronic Kidney Dis 2005;12:177-186.
12. Essawy M, Soylemezoglu O, Muchaneta-Kubara E, Shortland J, Brown C, Nahas AE: Myofibroblasts and the progression of diabetic nephropathy. Nephrol Dial Transplant 1997;12:43-50.
13. Ina K, Kitamura, H Tatsukawa S, Takayama T, Fujikura Y, Shimada T: Transformation of interstitial fibroblasts and tubulointerstitial fibrosis in diabetic nephropathy. Med Electron Microsc 2002;35:87-95.
14. Simonson MS: Phenotypic transitions and fibrosis in diabetic nephropathy. Kidney Int 2007;71:846-854.
15. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878.
16. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
17. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
18. Liu BC, Chen Q, Luo DD, Sun J, Phillips AO, Ruan XZ, Liu NF: Mechanisms of irbesartan in prevention of renal lesion in streptozotocin-induced diabetic rats. Acta Pharmacol Sin 2003;24:67-73.
19. Riser BL, Denichilo M, Cortes P, Baker C, Grondini JM, Yee J, Narins RG: Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 2000;11:25-38.
20. Coimbra TM, Janssen U, Gröne TO, Ostendorf T, Kunter U, Schmidt H, Brabant G, Floege J: Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 2000;57:167-182.
21. Li Y, Yang J, Dai C, Wu C, Liu Y: Role for integrin-linked kinase in mediating tubular epithelial to mesenchymal transition and renal interstitial fibrogensis. J Clin Invest 2003;112:503-516.
22. Oldfield MD, Bach LA, Forbes JM, Nikolic-Paterson D, McRobert A, Thallas V, Atkins RC, Osicka T, Jerums G, Cooper ME: Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 2001;108:1853-1863.
23. Bottinger EP, Bitzer M: TGF-beta signaling in renal disease. J Am Soc Nephrol 2002;13:2600-2610.
24. Russo LM, del Re E, Brown D, Lin HY: Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGFbeta type II receptor. Diabetes 2007;56:380-388.
25. Fan JM, Ng YY, Hill PA, Nikolic-Paterson DJ, Mu W, Atkins RC, Lan HY: Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney Int 1999;56:1455-1467.
26. Frazier KS, Williams S, Kothapalli D, Klapper H, Grotendorst GR: Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J Invest Dermatol 1996;107:404-411.
27. Zhang C, Meng X, Zhu Z, Liu J, Deng A: Connective tissue growth factor regulates the key events in tubular epithelial to myofibroblast transition in vitro. Cell Biol Int 2004;28:863-873.
28. Burns WC, Twigg SM, Forbes JM: Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol 2006;17:2484-2494.
29. Grotendorst GR, Duncan MR: Individual domains of connective tissue growth factor regulate fibroblast proliferation and myofibroblast differentiation. FASEB J 2005;19:729-738.
30. Wiecek A, Chudek J, Kokot F: Role of angiotensin II in the progression of diabetic nephropathy - therapeutic implications. Nephrol Dial Transplant 2003;18:v16-v20.
31. Zhang SL, Filep JG, Hohman TC, Tang SS, Ingelfinger JR, Chan JS: Molecular mechanisms of glucose action on angiotensinogen gene expression in rat proximal tubule cells. Kidney Int 1999;55:454-464.
32. Zimpelmann J, Kumar D, Levine DZ, Wehbi G, Imig JD, Navar LG, Burns KD: Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat. Kidney Int 2000;58:2320-2330.
33. Ruperez M, Ruiz-Ortega M, Esteban V, Lorenzo O, Mezzano S, Plaza JJ, Eqido J: Angiotensin II increases connective tissue growth factor in the kidney. Am J Pathol 2003;163:1937-1947.
34. Liu BC, Chen L, Sun J, Huang HQ, Ma KL, Liu H, Liu DJ, Zhang XL: Connective tissue growth factor-mediated angiotensin II-induced hypertrophy of proximal tubular cells. Nephron Exp Nephrol 2006;103:e16-e26.
35. Yang J, Dai C, Liu Y: Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice. J Am Soc Nephrol 2002;13:2464-2477.